{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
  "id": "02964020",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
  "summary": "### **June Quarter FY 2026 Investor Update \u2013 Material Information**  \n\n#### **Key Highlights:**  \n- **Combogesic IV\u00ae launched in Canada** \u2013 First sales under AFT\u2019s Canadian subsidiary, targeting the non-opioid pain management market amid Canada\u2019s opioid crisis.  \n- **Extended US licensing agreement with Hikma Pharmaceuticals** \u2013 Covers both **Combogesic IV** (IV form) and **Combogesic Rapid** (tablet form) for broader US commercialisation; restructured profit-sharing model.  \n- **R&D Pipeline Progress:**  \n  - *Antibiotic eyedrop* \u2013 Pre-IND filed with FDA; IND targeted before year-end.  \n  - *Strawberry Birthmarks topical treatment* \u2013 Pre-IND filing expected this year.  \n  - *Novel injectable iron* \u2013 IND filing planned by year-end.  \n  - *New project* \u2013 Improved formulation targeting a **US$180M** niche market, expected FY27 filing.  \n- **Pediatric Maxigesic IV study** \u2013 Prep underway to expand label into pediatric pain management.  \n- **Global expansion** \u2013 Canada joins existing operations in Singapore, Hong Kong, South Africa, US, EU, and UK; further OTC and in-licensed product launches planned for FY26.  \n\n*No financial or capital structure updates disclosed.*",
  "usage": {
    "prompt_tokens": 2426,
    "completion_tokens": 283,
    "total_tokens": 2709,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T21:44:19.539386"
}